Natera (NASDAQ:NTRA – Get Free Report) announced its earnings results on Thursday. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14), FiscalAI reports. Natera had a negative net margin of 5.66% and a negative return on equity of 8.73%. The business had revenue of $793.98 million during the quarter, compared to the consensus estimate of $707.54 million. During the same period in the previous year, the firm posted ($0.64) EPS. The company’s revenue was up 34.1% compared to the same quarter last year.
Here are the key takeaways from Natera’s conference call:
- Natera reported a record quarter, processing about 1.09 million tests, up 22%, and generating $794 million in revenue, up 34% year over year—or more than 40% excluding revenue true-ups. Clinical MRD volumes rose 56% to approximately 316,000 units.
- The company raised its 2026 revenue guidance to $3.005 billion–$3.035 billion, an increase of $140 million at the midpoint. It also reported 65% gross margin and said losses narrowed while it generated cash.
- Management highlighted new Medicare coverage for Signatera surveillance in early-stage liver cancer, nine to ten additional MolDX submissions in progress, and plans to launch colorectal and bladder cancer testing in Japan pending reimbursement and pricing. Executives said the coverage pipeline could support further Signatera ASP growth, though timing and outcomes remain uncertain.
- Natera set a goal of doubling revenue to $6 billion by 2029, primarily through continued growth in oncology testing, higher Signatera ASPs, international expansion, and pharma and data services. Management expects early cancer detection to contribute relatively little to that target in 2028–2029.
- The company plans to increase investment to support clinical trials, pharma and data demand, and early cancer detection; operating expenses are expected to grow 10%–12% in 2027. Management also cautioned that newer products may weigh on near-term costs and gross margins, although it expects cost improvements over time.
Natera Trading Down 14.6%
NASDAQ NTRA traded down $53.09 on Friday, hitting $310.67. The company’s stock had a trading volume of 5,775,619 shares, compared to its average volume of 1,711,005. Natera has a 1-year low of $181.00 and a 1-year high of $437.41. The company’s 50-day moving average is $380.25 and its 200 day moving average is $269.68.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Citigroup increased their price objective on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Royal Bank Of Canada boosted their target price on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. Leerink Partners set a $330.00 target price on shares of Natera in a research report on Friday, August 7th. Stephens upped their price target on shares of Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Robert W. Baird set a $348.00 price target on shares of Natera in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $391.69.
Read Our Latest Stock Analysis on NTRA
Natera News Roundup
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
- Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
- Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
- Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
- Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results
Insider Buying and Selling
In related news, CEO Steven Chapman sold 3,801 shares of Natera stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $411.80, for a total value of $1,565,251.80. Following the transaction, the chief executive officer directly owned 87,431 shares of the company’s stock, valued at $36,004,085.80. The trade was a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 302 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $400.01, for a total transaction of $120,803.02. Following the completion of the sale, the insider directly owned 195,276 shares in the company, valued at approximately $78,112,352.76. This represents a 0.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 53,573 shares of company stock worth $19,856,400. Corporate insiders own 5.05% of the company’s stock.
Natera Company Profile
Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.
In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
The company also provides Prospera, a molecular test used to help assess organ transplant rejection.
Featured Stories
- Five stocks we like better than Natera
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
